The inhibitory influence of carvacrol on behavioral modifications, brain oxidation, and general inflammation triggered by paraquat exposure through inhalation

Article

Author: Beigoli, Sima ; Sarir, Hadi ; Hosseini, Mahmoud ; Boskabady, Mohammad Hossein ; Khosravi, Reyhaneh ; Behrouz, Sepideh ; Sarbaz, Parisa ; Amirahmadi, Sabiheh

The current study investigated how carvacrol (C) can prevent behavioral and brain oxidative changes, along with systemic inflammation caused by inhaled paraquat (PQ). Control rats exposed to saline solution, whereas six rat groups were subjected to PQ aerosols at a concentration of 54mg/m³ in 16 days. The PQ-exposed groups received saline (PQ group), C at dosages of 20 (C-L) and 80mg/kg/day (C-H), dexamethasone at a dosage of 0.03mg/kg/day, pioglitazone at dose of 5 and 10mg/kg/day (Pio-L and Pio-H), and a combination of C-L + Pio-L. Various parameters were assessed following the end of the treatment duration. There were marked elevation in total and differential white blood cell counts (WBCs), and malondialdehyde levels in the blood, hippocampus, and cerebral tissue but, thiol, superoxide dismutase (SOD), and catalase (CAT) exhibited a notable decrease (p < 0.05 to p < 0.001). The escape delay and traveled distance exhibited enhancement, however, on the probe day, the duration spent in the target quadrant and the time taken to enter the dark room at 3, 24, 48, and 72hours post an electrical shock, showed a reduction in the PQ group (P<0.05 to P<0.001). Inhaled PQ-induced changes were significantly improved in C, Pio, Dexa, and C-L + Pio-L treated groups (P<0.05 to P<0.001). The effects of C-L + Pio-L on most measured variables were higher than C-L and Pio-L (P<0.05 to P<0.001). C improved PQ-induced changes similar to dexamethasone and C-L showed additive effects when administered in combination with Pio.

15 Jul 2007·Journal of Chinese Integrative Medicine

Dinggui Oil Capsule in treating irritable bowel syndrome with stagnation of qi and cold: a prospective, multi-center, randomized, placebo-controlled, double-blind trial

Article

Author: Fan, Zong-jiang ; Zhang, Rui-ming ; Zhang, Hai-rong ; Wang, Lei ; Yang, Xiao-nan ; Zhang, Fang-xing ; Jiang, Ming-de ; Yu, Zheng ; Xia, Qing ; Li, Ting-qian

OBJECTIVETo evaluate the efficacy and safety of Dinggui Oil Capsule in treating irritable bowel syndrome (IBS) with stagnation of qi and cold.METHODSA prospective, randomized, placebo-controlled, double-blind clinical study was undertaken. One hundred and ninety-eight patients with IBS and syndrome of stagnation of qi and cold were randomly divided into high-dose Dinggui Oil group (DGO-H, 1.2 g, 3 times daily; n=66), low-dose Dinggui Oil group (DGO-L, 0.8 g, 3 times daily, n=66), and placebo group (placebo, 5.0 g, 3 times daily, n=66). Patients in the three groups were all treated for 2 weeks.RESULTSThe total significant effective rates for IBS were 54.1%, 28.8% and 21.9% in the DGO-H, DGO-L, and placebo groups, and the total effective rates for the syndrome of stagnation of qi and cold were 54.1%, 25.8% and 23.4% in the three groups, respectively. Dinggui Oil Capsule showed a higher efficacy than the placebo in relieving the abdominal pain (P<0.01). No adverse effects were found in this trial.CONCLUSIONDinggui Oil Capsule is effective and safe in relieving abdominal pain due to IBS with stagnation of qi and cold.

100 Deals associated with Irino-L

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Infections	Preclinical	US	OyaGen, Inc.	05 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Irino-L

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation